ZAI LAB LIMITED Increase (Decrease) in Inventories
ZAI LAB LIMITED (ZLAB) reported Increase (Decrease) in Inventories of $21.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-06
- ZAI LAB LIMITED increase (decrease) in inventories for the quarter ending 2026-06-30 was $10.62M, a 19.34% increase year-over-year.
- ZAI LAB LIMITED increase (decrease) in inventories for the quarter ending 2026-03-31 was $11.21M, a 15.08% decline year-over-year.
- ZAI LAB LIMITED increase (decrease) in inventories for the quarter ending 2025-12-31 was $18.92M, a 3630.97% increase year-over-year.
- ZAI LAB LIMITED increase (decrease) in inventories for the quarter ending 2025-09-30 was $6.02M.
- ZAI LAB LIMITED increase (decrease) in inventories for fiscal 2025 was $47.03M.
- ZAI LAB LIMITED increase (decrease) in inventories for fiscal 2024 was -$3.90M, a 126.14% decline from fiscal 2023.
- ZAI LAB LIMITED increase (decrease) in inventories for fiscal 2023 was $14.91M, a 3.09% decline from fiscal 2022.
- ZAI LAB LIMITED increase (decrease) in inventories for fiscal 2022 was $15.38M, a 114.41% increase from fiscal 2021.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month | Increase (Decrease) in Inventories 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $10.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $21.83M 10-Q · filed 2026-08-06 | $40.74M derived: sum of 3 quarters · filed 2026-08-06 | $46.76M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $11.21M 10-Q · filed 2026-05-07 | $30.12M derived: sum of 2 quarters · filed 2026-05-07 | $36.14M derived: sum of 3 quarters · filed 2026-05-07 | $45.04M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $18.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $24.93M derived: sum of 2 quarters · filed 2026-02-26 | $33.83M derived: sum of 3 quarters · filed 2026-08-06 | $47.03M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $6.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $14.91M derived: sum of 2 quarters · filed 2026-08-06 | $28.11M 10-Q · filed 2025-11-06 | $28.62M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $8.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $22.10M 10-Q · filed 2026-08-06 | $22.60M derived: sum of 3 quarters · filed 2026-08-06 | $20.24M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $13.20M 10-Q · filed 2026-05-07 | $13.71M derived: sum of 2 quarters · filed 2026-05-07 | $11.34M derived: sum of 3 quarters · filed 2026-05-07 | $16.12M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $507.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.86M derived: sum of 2 quarters · filed 2026-02-26 | $2.92M derived: sum of 3 quarters · filed 2026-02-26 | -$3.90M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$2.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.42M derived: sum of 2 quarters · filed 2025-11-06 | -$4.40M 10-Q · filed 2025-11-06 | -$3.90M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $4.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$2.04M 10-Q · filed 2025-08-07 | -$1.54M derived: sum of 3 quarters · filed 2026-02-26 | $6.24M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | -$6.82M 10-Q · filed 2025-05-08 | -$6.32M derived: sum of 2 quarters · filed 2026-02-26 | $1.46M derived: sum of 3 quarters · filed 2026-02-26 | $1.40M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $499.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.28M derived: sum of 2 quarters · filed 2026-02-26 | $8.22M derived: sum of 3 quarters · filed 2026-02-26 | $14.91M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $7.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $7.72M derived: sum of 2 quarters · filed 2024-11-12 | $14.41M 10-Q · filed 2024-11-12 | $16.55M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | -$59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $6.63M 10-Q · filed 2024-08-06 | $8.77M derived: sum of 3 quarters · filed 2025-02-27 | $17.43M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $6.69M 10-Q · filed 2024-05-08 | $8.83M derived: sum of 2 quarters · filed 2025-02-27 | $17.49M derived: sum of 3 quarters · filed 2025-02-27 | $20.59M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $10.80M derived: sum of 2 quarters · filed 2025-02-27 | $13.91M derived: sum of 3 quarters · filed 2025-02-27 | $15.38M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $8.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $11.76M derived: sum of 2 quarters · filed 2023-11-07 | $13.23M 10-Q · filed 2023-11-07 | $20.66M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $3.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $4.58M 10-Q · filed 2023-08-07 | $12.00M derived: sum of 3 quarters · filed 2024-02-27 | $13.50M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $1.48M 10-Q · filed 2023-05-09 | $8.90M derived: sum of 2 quarters · filed 2024-02-27 | $10.39M derived: sum of 3 quarters · filed 2024-02-27 | $9.15M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $7.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $8.91M derived: sum of 2 quarters · filed 2024-02-27 | $7.68M derived: sum of 3 quarters · filed 2024-02-27 | $7.17M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $1.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $254.00K derived: sum of 2 quarters · filed 2022-11-09 | -$248.00K 10-Q · filed 2022-11-09 | $3.29M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | -$1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$1.74M 10-Q · filed 2022-08-09 | $1.80M derived: sum of 3 quarters · filed 2023-03-01 | $4.86M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | -$502.00K 10-Q · filed 2022-05-10 | $3.04M derived: sum of 2 quarters · filed 2023-03-01 | $6.09M derived: sum of 3 quarters · filed 2023-03-01 | $6.62M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | $3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $6.60M derived: sum of 2 quarters · filed 2023-03-01 | $7.12M derived: sum of 3 quarters · filed 2023-03-01 | $7.17M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $3.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $3.59M derived: sum of 2 quarters · filed 2021-11-09 | $3.63M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $526.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $571.00K 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $45.00K 10-Q · filed 2021-05-10 | ||||
| 2019-12-31 | $6.00M 10-K · filed 2022-03-01 | ||||
| 2019-06-30 | $137.00K 6-K · filed 2020-09-11 | ||||
| 2018-12-31 | $4.00K 10-K · filed 2021-03-01 | $3.82K 20-F · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |